Actively Recruiting
Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-30
100
Participants Needed
1
Research Sites
353 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.
CONDITIONS
Official Title
Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic
- Patients who have received treatment for breast cancer or gynecologic cancer since January 2010
- Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data
You will not qualify if you...
- No exclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, 40138
Actively Recruiting
Research Team
C
Claudio Zamagni, MD
CONTACT
C
Cinzia Pizzirani, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here